346 related articles for article (PubMed ID: 2469657)
21. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
22. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.
Yang JC; Mulé JJ; Rosenberg SA
J Immunol; 1986 Jul; 137(2):715-22. PubMed ID: 2873187
[TBL] [Abstract][Full Text] [Related]
23. Similarities and distinctions between murine natural killer cells and lymphokine-activated killer cells.
Merluzzi VJ; Smith MD; Last-Barney K
Cell Immunol; 1986 Jul; 100(2):563-9. PubMed ID: 3489533
[TBL] [Abstract][Full Text] [Related]
24. Interleukin 2-induced proliferation of murine natural killer cells in vivo.
Biron CA; Young HA; Kasaian MT
J Exp Med; 1990 Jan; 171(1):173-88. PubMed ID: 1688606
[TBL] [Abstract][Full Text] [Related]
25. The expression and functional involvement of laminin-like molecules in non-MHC restricted cytotoxicity by human Leu-19+/CD3- natural killer lymphocytes.
Schwarz RE; Hiserodt JC
J Immunol; 1988 Nov; 141(10):3318-23. PubMed ID: 3263421
[TBL] [Abstract][Full Text] [Related]
26. Recombinant interleukin 2 allows the differentiation of Thy 1.2+ LAK cells from nude mouse spleen cells.
Nishimura T; Yagi H; Uchiyama Y; Hashimoto Y
Immunol Lett; 1986 Mar; 12(2-3):77-82. PubMed ID: 2873098
[TBL] [Abstract][Full Text] [Related]
27. Effector and precursor phenotypes of lymphokine-activated killer cells in mice with severe combined immunodeficiency (scid) and athymic (nude) mice.
Hasui M; Saikawa Y; Miura M; Takano N; Ueno Y; Yachie A; Miyawaki T; Taniguchi N
Cell Immunol; 1989 Apr; 120(1):230-9. PubMed ID: 2784720
[TBL] [Abstract][Full Text] [Related]
28. Phenotypic characterization of murine lymphokine-activated killer cells.
Owen-Schaub LB; Abraham SR; Hemstreet GP
Cell Immunol; 1986 Dec; 103(2):272-86. PubMed ID: 2879640
[TBL] [Abstract][Full Text] [Related]
29. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
30. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
Vujanovic NL; Herberman RB; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
[TBL] [Abstract][Full Text] [Related]
31. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
[TBL] [Abstract][Full Text] [Related]
32. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
McMannis JD; Fisher RI; Creekmore SP; Braun DP; Harris JE; Ellis TM
J Immunol; 1988 Feb; 140(4):1335-40. PubMed ID: 3257776
[TBL] [Abstract][Full Text] [Related]
33. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
[TBL] [Abstract][Full Text] [Related]
34. Induction of murine lymphokine-activated killer cells by recombinant IL-7.
Lynch DH; Miller RE
J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262
[TBL] [Abstract][Full Text] [Related]
35. Identification of macromolecular insoluble cold globulin (MICG) as a new marker shared by NK and ADCC cells, but not expressed by NC cells.
Campos-Perera C; Murgita RA; Hauptman SP; Gronvik KO
Immunology; 1986 Sep; 59(1):101-7. PubMed ID: 2428732
[TBL] [Abstract][Full Text] [Related]
36. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
[TBL] [Abstract][Full Text] [Related]
37. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
38. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
39. The mechanism of IL-2-mediated protection against GVHD in mice. II. Protection occurs independently of NK/LAK cells.
Sykes M; Abraham VS
Transplantation; 1992 May; 53(5):1063-70. PubMed ID: 1533968
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires.
Fox BA; Rosenberg SA
Cancer Immunol Immunother; 1989; 29(3):155-66. PubMed ID: 2786456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]